Anti-Obesity “Biochemical Cigarette” Exploits Body’s Responses to Cold and Smoking

Researchers in Europe and Australia have developed an anti-obesity “chemical cigarette” that exploits the body’s natural responses to both cold exposure and smoking. The...

Targeting Glioblastoma by Depriving Brain Cancer Cells of Cholesterol

Study identified a metabolic vulnerability in the aggressive and incurable brain cancer glioblastoma and shown how it can potentially be exploited for therapy.

Hope for Autism Lies in Century-Old Drug

Testing a new theory, researchers have used a newly discovered function of an old drug to restore cell communications in a mouse model of autism, reversing symptoms of the disorder.

Softening Up Chemo-Resistant Cancer Cells

Scientists at the University of California San Diego (UCSD) have identified a gene that is involved in controlling the sensitivity of cancer cells to...

Zika’s Balloon Popped by Peptide Needle

A new antiviral drug candidate attacks the Zika virus where it may be most vulnerable—the lipid membrane, which envelopes Zika’s RNA payload. The drug...

Novozymes, Almac Ally to Offer Drug Targeting, Pharmacokinetics Service

Novozymes Biopharma is teaming up with Almac to provide a combined service for drug development applications in the field of drug targeting and pharmacokinetic improvements.

Triple-Acting Diabetes Drug Reverses Memory Loss in Alzheimer’s Disease Mouse Models

Studies in a mouse model of Alzheimer’s disease (AD) have shown how a drug that was originally developed to treat type 2 diabetes can reverse memory loss and boost neuroprotection in a mouse model of AD.

Ophthotech Expands Eye Disease Pipelines of Small Molecule, Gene Therapy Candidates

Ophthotech has expanded its eye disease treatment pipeline today by acquiring a small-molecule, age-related retinal disease therapy developer, as well as launching its third...

Breast Cancer Genetic Test May Help Women Forgo Chemotherapy

Prospective study finds no benefit of adding chemotherapy to hormone treatment for early breast cancer patients who have an intermediate Oncotype Dx gene expression assay score

Recently Featured

Stay Connected

Scroll Up